| scholarly article | Q13442814 |
| P356 | DOI | 10.1023/A:1016092525901 |
| P698 | PubMed publication ID | 8692732 |
| P2093 | author name string | Y Wang | |
| D F Welty | |||
| P2860 | cites work | Transport of gabapentin, a gamma-amino acid drug, by system l alpha-amino acid transporters: a comparative study in astrocytes, synaptosomes, and CHO cells | Q72169569 |
| Gabapentin anticonvulsant action in rats: disequilibrium with peak drug concentrations in plasma and brain microdialysate | Q72270715 | ||
| Investigation of the distribution of EAB 515 to cortical ECF and CSF in freely moving rats utilizing microdialysis | Q72397759 | ||
| [3H]gabapentin may label a system-L-like neutral amino acid carrier in brain | Q72770910 | ||
| Microdialysis--theory and application | Q34256942 | ||
| Microdialysis calibration using retrodialysis and zero-net flux: application to a study of the distribution of zidovudine to rabbit cerebrospinal fluid and thalamus | Q34347132 | ||
| Polarity of the Blood-Brain Barrier: Neutral Amino Acid Transport into Isolated Brain Capillaries | Q40174081 | ||
| A survey on quantitative microdialysis: theoretical models and practical implications | Q40713309 | ||
| The internal reference technique in microdialysis: A practical approach to monitoring dialysis efficiency and to calculating tissue concentration from dialysate samples | Q43738128 | ||
| Selected CSF biochemistry and gabapentin concentrations in the CSF and plasma in patients with partial seizures after a single oral dose of gabapentin | Q45012245 | ||
| Diet and uptake of aldomet by the brain: competition with natural large neutral amino acids | Q48265693 | ||
| An in situ brain perfusion technique to study cerebrovascular transport in the rat. | Q48627674 | ||
| The use of an "internal standard" for control of the recovery in microdialysis. | Q51720194 | ||
| Zidovudine transport in the rabbit brain during intravenous and intracerebroventricular infusion. | Q52337785 | ||
| Microdialysis study of zidovudine (AZT) transport in rat brain. | Q52387285 | ||
| A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma | Q70618602 | ||
| Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys | Q71845183 | ||
| P433 | issue | 3 | |
| P921 | main subject | blood–brain barrier | Q221694 |
| pharmacokinetics | Q323936 | ||
| gabapentin | Q410352 | ||
| P304 | page(s) | 398-403 | |
| P577 | publication date | 1996-03-01 | |
| P1433 | published in | Pharmaceutical Research | Q7180737 |
| P1476 | title | The simultaneous estimation of the influx and efflux blood-brain barrier permeabilities of gabapentin using a microdialysis-pharmacokinetic approach. | |
| P478 | volume | 13 |
| Q28343920 | A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain |
| Q59806236 | Alzheimer's Disease Phenotype or Inflammatory Insult Does Not Alter Function of L-Type Amino Acid Transporter 1 in Mouse Blood-Brain Barrier and Primary Astrocytes |
| Q91718128 | Applicability of free drug hypothesis to drugs with good membrane permeability that are not efflux transporter substrates: A microdialysis study in rats |
| Q41429090 | Application of microdialysis in pharmacokinetic studies |
| Q35013512 | Assessment of cutaneous drug delivery using microdialysis |
| Q90300767 | Beyond the Blood:Brain Barrier: The Importance of Central Nervous System (CNS) Pharmacokinetics for the Treatment of CNS Tumors, Including Diffuse Intrinsic Pontine Glioma |
| Q48469492 | Blood-brain barrier equilibration of codeine in rats studied with microdialysis. |
| Q43735600 | Brain microdialysis and PK/PD correlation of pregabalin in rats |
| Q48197949 | Brain penetration and in vivo recovery of NMDA receptor antagonists amantadine and memantine: a quantitative microdialysis study |
| Q45268262 | Capillary electrochromatography of caffeine and its metabolites in rat brain microdialysate |
| Q73850482 | Carrier-mediated or specialized transport of drugs across the blood-brain barrier |
| Q30651426 | Challenges of using in vitro data for modeling P-glycoprotein efflux in the blood-brain barrier |
| Q47288144 | Chronic treatment with lithium and pretreatment with excess inositol reduce inositol pool size in astrocytes by different mechanisms |
| Q41215905 | Combined Microdialysis-Tumor Homogenate Method for the Study of the Steady State Compartmental Distribution of a Hydrophobic Anticancer Drug in Patient-Derived Xenografts |
| Q44635237 | Comparing translational population-PBPK modelling of brain microdialysis with bottom-up prediction of brain-to-plasma distribution in rat and human |
| Q32181067 | Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. |
| Q30739850 | Determination of unbound drug concentration and protein-drug binding fraction in plasma |
| Q47668140 | Distribution of lacosamide in the rat brain assessed by in vitro slice technique |
| Q73197228 | Drug equilibration across the blood-brain barrier--pharmacokinetic considerations based on the microdialysis method |
| Q57677287 | Drug transport across the blood-brain barrier |
| Q36952858 | Effects of gabapentin on cocaine self-administration, cocaine-triggered relapse and cocaine-enhanced nucleus accumbens dopamine in rats |
| Q33985116 | How to measure drug transport across the blood-brain barrier |
| Q61804384 | Hypoxia affects Slc7a5 expression through HIF-2α in differentiated neuronal cells |
| Q41139588 | Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain |
| Q48640209 | In-vivo microdialysis study of the distribution of cisplatin into brain tumour tissue after intracarotid infusion in rats with 9L malignant glioma. |
| Q42221833 | LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substrates |
| Q35206798 | Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats |
| Q48339488 | Methodological aspects of the use of a calibrator in in vivo microdialysis-further development of the retrodialysis method |
| Q34100148 | Methodological issues in microdialysis sampling for pharmacokinetic studies |
| Q34100196 | Microdialysis in the study of drug transporters in the CNS. |
| Q42283115 | Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecid-sensitive transport |
| Q33751096 | Molecular modeling and ligand docking for solute carrier (SLC) transporters |
| Q44435883 | Morphine blood-brain barrier transport is influenced by probenecid co-administration |
| Q47949927 | Novel CNS drug discovery and development approach: model-based integration to predict neuro-pharmacokinetics and pharmacodynamics |
| Q37023904 | On the rate and extent of drug delivery to the brain. |
| Q38186650 | Overview of experimental models of the blood-brain barrier in CNS drug discovery |
| Q48607094 | Permeability analysis of neuroactive drugs through a dynamic microfluidic in vitro blood-brain barrier model. |
| Q50026347 | Pharmacokinetic assessment of cooperative efflux of the multi-targeted kinase inhibitor ponatinib across the blood-brain barrier. |
| Q48598406 | Pharmacokinetic consequences of active drug efflux at the blood-brain barrier. |
| Q49108658 | Pharmacokinetic-pharmacodynamic modelling of morphine transport across the blood-brain barrier as a cause of the antinociceptive effect delay in rats--a microdialysis study. |
| Q40094164 | Pharmacokinetic/Pharmacodynamic Relationship of Gabapentin in a CFA-induced Inflammatory Hyperalgesia Rat Model |
| Q37207750 | Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach |
| Q37554396 | Prediction of antiepileptic drug efficacy: the use of intracerebral microdialysis to monitor biophase concentrations |
| Q90494434 | Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1) |
| Q47309054 | Side effects associated with current and prospective antimigraine pharmacotherapies. |
| Q41997254 | Simultaneous central nervous system distribution and pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of norfloxacin administered at a convulsant dose in rats. |
| Q48445357 | Simultaneous microdialysis in brain and blood of the mouse: extracellular and intracellular brain colchicine disposition. |
| Q86250333 | Site of effect of LY2951742 for migraine prophylaxis--authors' reply |
| Q49395684 | Structural basis for amino acid transport by the CAT family of SLC7 transporters. |
| Q36747640 | Structure-based ligand discovery for the Large-neutral Amino Acid Transporter 1, LAT-1 |
| Q34100188 | The use of microdialysis in CNS drug delivery studies. Pharmacokinetic perspectives and results with analgesics and antiepileptics |
| Q99711228 | Toward a Systematic Structural and Functional Annotation of Solute Carriers Transporters-Example of the SLC6 and SLC7 Families |
| Q36341660 | Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling |
| Q39705093 | Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas |
Search more.